10-Q: Oaktree Acquisition Corp. III Reports Q2 2025 Results

Oaktree Acquisition Corp. III Life Sciences, a blank check company, reported a net income of $1.87 million for Q2 2025, primarily from trust account interest, as it continues its search for a business combination target.

Summary

• Oaktree Acquisition Corp. III Life Sciences, a blank check company (SPAC), reported a net income of $1,874,343 for the three months ended June 30, 2025, and $3,533,134 for the six months ended June 30, 2025.
• The income was primarily derived from interest earned on cash held in the Trust Account, totaling $2,144,153 for the quarter and $4,247,746 for the six-month period.
• General and administrative expenses were $269,810 for the quarter and $714,612 for the six-month period.
• As of June 30, 2025, the company held $197,576,768 in its Trust Account and had $1,385,359 in cash outside the Trust Account.
• Total assets stood at $199,175,668, with total liabilities of $8,137,983.
• The company has an accumulated deficit of $6,539,621 as of June 30, 2025.
• Net cash used in operating activities for the six months ended June 30, 2025, was $221,685, offset by $250,000 withdrawn from the Trust Account for working capital purposes.
• The company has 19,783,010 Class A ordinary shares and 4,799,758 Class B ordinary shares issued and outstanding as of August 12, 2025.
• There are 3,956,601 warrants outstanding, exercisable at $11.50 per share, expiring five years after a business combination.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The company is performing as expected for a SPAC in its search phase, generating interest income on its trust account and managing its administrative expenses. The management change is routine. The primary uncertainty remains the successful identification and completion of a business combination, which is inherent to the SPAC model.

Positives

• Generated significant non-operating income from interest on the Trust Account, with $2,144,153 for the quarter and $4,247,746 for the six months ended June 30, 2025.
• Maintained a strong cash position in the Trust Account, growing from $193,579,022 at December 31, 2024, to $197,576,768 at June 30, 2025.
• Sufficient liquidity available for working capital needs for at least one year from the issuance date of the financial statements, including the ability to withdraw $250,000 per annum from Trust Account interest.

Negatives

• The company has no operating history and has not generated any operating revenues to date, relying solely on interest income from the Trust Account.
• Accumulated deficit increased to $6,539,621 as of June 30, 2025, from $6,075,009 at December 31, 2024.
• Incurred $714,612 in general and administrative expenses for the six months ended June 30, 2025, contributing to the accumulated deficit.
• The company is a blank check company and has not yet identified or completed a business combination, posing uncertainty regarding its future operations.

Risks

• No operating history or revenues, making it difficult to evaluate the ability to achieve business objectives.
• Uncertainty in selecting an appropriate target business or businesses for a business combination.
• Inability to complete the initial business combination within the 24-month Combination Period, which would lead to liquidation.
• Reliance on the performance of a prospective target business, which is currently unknown.
• Challenges in retaining or recruiting officers, key employees, or directors following a business combination.
• Potential conflicts of interest due to officers and directors allocating their time to other businesses.
• Risk of not being able to obtain additional financing required to complete a business combination.
• The size and quality of the pool of prospective target businesses may be limited.
• High potential for redemptions by public shareholders, which could reduce funds available for a business combination.
• General economic and political conditions, including recessions, interest rates, inflation, and geopolitical tensions (e.g., Russia-Ukraine conflict, Middle East conflict), could adversely affect the ability to complete a business combination.
• The Sponsor's ability to satisfy indemnity obligations is uncertain, as its only assets are securities of the company.
• Warrants may expire worthless if a business combination is not consummated within the Combination Period.

Future Outlook

The company expects to continue incurring significant costs in its pursuit of an acquisition target. It does not anticipate generating any operating revenues until after the completion of its initial business combination. Non-operating income is expected to continue from interest earned on the proceeds held in the Trust Account. Management believes it has sufficient liquidity for at least one year and does not foresee needing to raise additional funds for current business operations, though this could change if target identification and due diligence costs exceed estimates.

Management Comments

• "We have neither engaged in any operations nor generated any revenues to date. Our only activities from inception to June 30, 2025 were organizational activities, those necessary to prepare for the initial public offering, described below, and, after the initial public offering, identifying a target company for a business combination."
• "We do not expect to generate any operating revenues until after the completion of our business combination."
• "We do not believe it will need to raise additional funds in order to meet the expenditures required for operating its business. However, if the estimate of the costs of identifying a target business, undertaking in-depth due diligence and negotiating a Business Combination are less than the actual amount necessary to do so, the Company may have insufficient funds available to operate its business prior to the initial Business Combination."

Industry Context

As a Special Purpose Acquisition Company (SPAC) in the 'blank check' phase, Oaktree Acquisition Corp. III Life Sciences operates within a unique segment of the financial industry. Its primary objective is to identify and merge with a private company, specifically within the life sciences sector, to bring it public. The company's current financial performance, characterized by interest income and administrative expenses, is typical for a SPAC prior to a business combination. Its success is entirely dependent on its ability to identify a suitable target and complete a de-SPAC transaction, which is subject to market conditions, investor sentiment towards SPACs, and the attractiveness of potential targets in the life sciences industry.

Comparison to Industry Standards

• As a SPAC, direct comparison to operating companies' financial results is not applicable. Its performance is measured by its ability to preserve and grow its trust account value and efficiently manage its operating expenses while searching for a target.
• The interest earned on the Trust Account, totaling $4,247,746 for the six months, reflects the prevailing interest rate environment and the size of the trust, which is standard for a SPAC of this initial offering size ($191.99 million).
• General and administrative expenses of $714,612 for six months, including a $25,000 monthly administrative fee to the Sponsor, are typical for a SPAC managing its public company obligations and search efforts.
• The company's structure, including the 24-month combination period and warrant terms, aligns with common SPAC industry practices, such as those seen in other Oaktree-sponsored SPACs or similar blank check companies listed on Nasdaq.

Management Changes

Corporate Governance

Related Party Transactions

• The Sponsor (Oaktree Acquisition Holdings III LS, LLC) holds 4,799,758 Class B ordinary shares (Founder Shares) and 583,981 Private Placement Units.
• A promissory note of $11,824 is outstanding to the Sponsor, due on demand.
• The company pays the Sponsor $25,000 per month for office space, secretarial, and administrative services, totaling $150,000 for the six months ended June 30, 2025.
• The company has an indemnification agreement with the Sponsor and its affiliates for liabilities related to the company's affairs, excluding access to Trust Account funds.
• The Sponsor or its affiliates may provide Working Capital Loans, convertible into private placement units.

Stakeholder Impact

• Shareholders: Public shareholders have redemption rights for their Class A ordinary shares at a pro rata portion of the Trust Account, providing a floor to their investment value if a business combination is not completed or approved. Warrants will expire worthless if no business combination occurs.
• Sponsor: The Sponsor holds Founder Shares and Private Placement Units, which are subject to lock-up periods and conversion terms. The Sponsor also provides administrative services and may provide working capital loans, indicating ongoing financial and operational involvement.
• Underwriters: Entitled to deferred underwriting commissions of $6,719,660 upon completion of a business combination, aligning their interests with a successful transaction.

Next Steps

• Continue the search for an initial Business Combination target.
• Complete one or more initial Business Combinations having an aggregate fair market value of at least 80% of the net assets held in the Trust Account.
• File a registration statement covering Class A ordinary shares issuable upon exercise of warrants within 20 business days after the closing of the initial Business Combination.

Key Dates

Recommendation

As a blank check company (SPAC) in its pre-business combination phase, Oaktree Acquisition Corp. III Life Sciences has no operational revenue or core business to evaluate for traditional investment metrics. Its value is primarily tied to the cash held in its Trust Account and the potential for a future business combination. The current filing indicates stable financial management for a SPAC, with interest income offsetting administrative expenses. The recent CFO change is a routine personnel update and not indicative of operational distress. Investors are essentially holding cash plus a call option on a future, as-yet-unidentified life sciences company. Therefore, a 'hold' recommendation is appropriate for existing investors, as there's no new information to warrant a change in stance, while new investors should await a definitive business combination announcement before making a decision.

Keywords

SPAC, Blank Check Company, Acquisition, Business Combination, Life Sciences, Oaktree, 10-Q, SEC Filing, Trust Account, Warrants, Redemption, Financial Results